KA Stock Overview
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Kineta, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.56 |
52 Week High | US$5.39 |
52 Week Low | US$0.49 |
Beta | 0 |
1 Month Change | -77.95% |
3 Month Change | -85.68% |
1 Year Change | -82.58% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -85.18% |
Recent News & Updates
Recent updates
Shareholder Returns
KA | US Biotechs | US Market | |
---|---|---|---|
7D | -0.2% | 0.2% | 1.3% |
1Y | -82.6% | 10.2% | 29.8% |
Return vs Industry: KA underperformed the US Biotechs industry which returned 9.8% over the past year.
Return vs Market: KA underperformed the US Market which returned 30.4% over the past year.
Price Volatility
KA volatility | |
---|---|
KA Average Weekly Movement | 21.7% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KA's share price has been volatile over the past 3 months.
Volatility Over Time: KA's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 12 | n/a | https://kinetabio.com |
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug.
Kineta, Inc. Fundamentals Summary
KA fundamental statistics | |
---|---|
Market cap | US$7.12m |
Earnings (TTM) | -US$14.10m |
Revenue (TTM) | US$5.44m |
1.1x
P/S Ratio-0.4x
P/E RatioIs KA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
KA income statement (TTM) | |
---|---|
Revenue | US$5.44m |
Cost of Revenue | US$9.02m |
Gross Profit | -US$3.58m |
Other Expenses | US$10.52m |
Earnings | -US$14.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.29 |
Gross Margin | -65.80% |
Net Profit Margin | -259.08% |
Debt/Equity Ratio | 25.2% |
How did KA perform over the long term?
See historical performance and comparison